MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Glaukos Corp

Cerrado

SectorSanidad

86.83 -13.25

Resumen

Variación precio

24h

Actual

Mínimo

86.67

Máximo

99.97

Métricas clave

By Trading Economics

Ingresos

-12M

-34M

Ventas

8.8M

105M

BPA

-0.4

Margen de beneficios

-31.83

Empleados

995

EBITDA

-12M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+64.43% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.2B

5.8B

Apertura anterior

100.08

Cierre anterior

86.83

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Glaukos Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 abr 2025, 23:04 UTC

Principales Noticias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 abr 2025, 22:40 UTC

Principales Movimientos del Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 abr 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 abr 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 abr 2025, 23:43 UTC

Charlas de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 abr 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 abr 2025, 22:22 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 21:43 UTC

Principales Noticias
Ganancias

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 abr 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 abr 2025, 20:43 UTC

Charlas de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 abr 2025, 20:34 UTC

Principales Noticias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 abr 2025, 20:23 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 20:15 UTC

Adquisiciones, fusiones, absorciones

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 abr 2025, 19:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 abr 2025, 19:55 UTC

Charlas de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 abr 2025, 19:21 UTC

Charlas de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 abr 2025, 19:15 UTC

Charlas de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 abr 2025, 18:45 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:45 UTC

Charlas de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 abr 2025, 18:39 UTC

Charlas de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 abr 2025, 18:38 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 18:30 UTC

Principales Noticias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 abr 2025, 18:20 UTC

Charlas de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 abr 2025, 18:18 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:17 UTC

Charlas de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 abr 2025, 18:04 UTC

Charlas de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 abr 2025, 17:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Glaukos Corp previsión

Precio Objetivo

By TipRanks

64.43% repunte

Estimación a 12 Meses

Media 164.5 USD  64.43%

Máximo 200 USD

Mínimo 110 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Glaukos Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

98.42 / 102.44Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.